Significant advances have been made in the treatment of non-small cell lung cancer (NSCLC), the most common form of lung cancer. The latest trial updates in oncogene-targeted therapy for patients with advanced ALK-positive NSCLC were presented during the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.